<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573738</url>
  </required_header>
  <id_info>
    <org_study_id>20200913</org_study_id>
    <nct_id>NCT04573738</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Robotic Assisted Transanal Total Mesorectal Excision for Rectal Cancer</brief_title>
  <official_title>Safety and Feasibility Study of Robotic Assisted Transanal Total Mesorectal Excision for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total mesorectal excision has greatly reduced the local recurrence rate of rectal cancer&#xD;
      after colorectal surgery. Transanal total mesorectal excision(TaTME) is potentially a&#xD;
      suitable option for patients with middle and low rectal cancer. Robotic systems are expected&#xD;
      to develop the advantages of TaTME to overcome the limitations of laparoscopic surgery. This&#xD;
      study aimed to investigate the safety and feasibility of robotic assisted transanal total&#xD;
      mesorectal excision in patients with rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TaTME is potentially a suitable option for patients with middle or low rectal cancer,&#xD;
      especially for males with obesity and a narrow pelvis.The da Vinci robotic system (Intuitive&#xD;
      Surgical, Sunnyvale, CA, USA) is expected to overcome the limitations of the laparoscopic&#xD;
      transanal approach for rectal surgery. Da Vinci Si Surgical System or da Vinci Xi Surgical&#xD;
      System would be used to performed Transanal total mesorectal excision. And the surgery would&#xD;
      performed by two-team approach. This study aimed to investigate the safety and feasibility of&#xD;
      robotic assisted transanal total mesorectal excision in patients with rectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The local recurrence rates of rectal cancer</measure>
    <time_frame>Two years after surgery</time_frame>
    <description>The incidence of local recurrence rectal cancer within two years after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of postoperative anastomotic leakage</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>The incidence of postoperative anastomotic leakage within 30 days after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The five-year survival rates</measure>
    <time_frame>Five years after surgery</time_frame>
    <description>The 5-year survival rates of rectal cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The distant metastasis rates of rectal cancer</measure>
    <time_frame>Five years after surgery</time_frame>
    <description>The incidence of distant metastasis rectal cancer within two years after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Perioperative Complication</condition>
  <arm_group>
    <arm_group_label>Robotic transanal surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic assisted transanal total mesorectal excision for rectal cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic transanal surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic transanal total mesorectal excision for rectal cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic assisted transanal total mesorectal excision</intervention_name>
    <description>Robotic assisted transanal total mesorectal excision for rectal cancer patients</description>
    <arm_group_label>Robotic transanal surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic assisted transanal total mesorectal excision</intervention_name>
    <description>Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients</description>
    <arm_group_label>Laparoscopic transanal surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathological biopsy confirmed adenocarcinoma of the rectum.&#xD;
&#xD;
          2. Preoperative assessment of tolerance to surgery without major organ dysfunction.&#xD;
&#xD;
          3. Patients must be able to understand and voluntarily sign written informed consent.&#xD;
&#xD;
          4. The surgical method is robotic assisted transanal total mesorectal excision&#xD;
&#xD;
          5. Distance of the edge of the tumour within 8 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient cannot tolerate the operation.&#xD;
&#xD;
          2. Refusal to sign informed consent.&#xD;
&#xD;
          3. Patients with distant metastasis of rectal cancer.&#xD;
&#xD;
          4. The surgical method was changed to miles or Hartman;&#xD;
&#xD;
          5. Unable to complete the follow - up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weidong Tong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Army Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haode Shen, MD</last_name>
    <phone>+8617783437391</phone>
    <email>imshd@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weidong Tong, MD</last_name>
    <phone>02368757955</phone>
    <email>vdtong@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daping hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Tong, Prof</last_name>
      <phone>86-023-68757956</phone>
      <email>tongweidong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Weidong Tong, Prof</last_name>
      <phone>86-13500321218</phone>
      <email>vdtong@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lee L, de Lacy B, Gomez Ruiz M, Liberman AS, Albert MR, Monson JRT, Lacy A, Kim SH, Atallah SB. A Multicenter Matched Comparison of Transanal and Robotic Total Mesorectal Excision for Mid and Low-rectal Adenocarcinoma. Ann Surg. 2019 Dec;270(6):1110-1116. doi: 10.1097/SLA.0000000000002862.</citation>
    <PMID>29916871</PMID>
  </reference>
  <reference>
    <citation>Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. 2017 Oct 24;318(16):1569-1580. doi: 10.1001/jama.2017.7219.</citation>
    <PMID>29067426</PMID>
  </reference>
  <reference>
    <citation>Atallah S, Martin-Perez B, Pinan J, Quinteros F, Schoonyoung H, Albert M, Larach S. Robotic transanal total mesorectal excision: a pilot study. Tech Coloproctol. 2014 Nov;18(11):1047-53. doi: 10.1007/s10151-014-1181-5. Epub 2014 Jun 24.</citation>
    <PMID>24957360</PMID>
  </reference>
  <reference>
    <citation>Ye J, Tian Y, Wang L, Ye Y, Zhang Y, Li F, Liu B, Tong W. [Robotic-assisted transanal total mesorectal excision for lower rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Aug 25;20(8):900-903. Chinese.</citation>
    <PMID>28836251</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Weidong Tong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Robotic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

